AU2013241776B2 - Basal insulin therapy - Google Patents

Basal insulin therapy Download PDF

Info

Publication number
AU2013241776B2
AU2013241776B2 AU2013241776A AU2013241776A AU2013241776B2 AU 2013241776 B2 AU2013241776 B2 AU 2013241776B2 AU 2013241776 A AU2013241776 A AU 2013241776A AU 2013241776 A AU2013241776 A AU 2013241776A AU 2013241776 B2 AU2013241776 B2 AU 2013241776B2
Authority
AU
Australia
Prior art keywords
diabetes
insulin
treatment
patient
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2013241776A
Other languages
English (en)
Other versions
AU2013241776A1 (en
Inventor
Hertzel Gerstein
Peter Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2013241776A1 publication Critical patent/AU2013241776A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: SANOFI
Application granted granted Critical
Publication of AU2013241776B2 publication Critical patent/AU2013241776B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013241776A 2012-03-28 2013-03-28 Basal insulin therapy Expired - Fee Related AU2013241776B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261616768P 2012-03-28 2012-03-28
US61/616,768 2012-03-28
US201261619641P 2012-04-03 2012-04-03
US61/619,641 2012-04-03
US201261624598P 2012-04-16 2012-04-16
US61/624,598 2012-04-16
US201261645909P 2012-05-11 2012-05-11
US61/645,909 2012-05-11
US201261701911P 2012-09-17 2012-09-17
US61/701,911 2012-09-17
PCT/EP2013/056661 WO2013144273A1 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Publications (2)

Publication Number Publication Date
AU2013241776A1 AU2013241776A1 (en) 2014-10-16
AU2013241776B2 true AU2013241776B2 (en) 2017-11-02

Family

ID=48044781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013241776A Expired - Fee Related AU2013241776B2 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Country Status (13)

Country Link
US (1) US20150065421A1 (enExample)
EP (1) EP2830650A1 (enExample)
JP (1) JP2015512908A (enExample)
KR (1) KR20150001757A (enExample)
CN (1) CN104334183A (enExample)
AU (1) AU2013241776B2 (enExample)
CA (1) CA2865823A1 (enExample)
HK (1) HK1201155A1 (enExample)
IN (1) IN2014KN02335A (enExample)
MX (1) MX2014011687A (enExample)
RU (1) RU2014143271A (enExample)
SG (1) SG11201405433XA (enExample)
WO (1) WO2013144273A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017108943A1 (en) * 2015-12-23 2017-06-29 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US20190357853A1 (en) * 2018-05-24 2019-11-28 Lizheng Shi Diabetes risk engine and methods thereof for predicting diabetes progression and mortality

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281793A1 (en) * 2003-01-14 2011-11-17 Aventis Pharmaceuticals Inc. Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes
WO2011161161A1 (en) * 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281793A1 (en) * 2003-01-14 2011-11-17 Aventis Pharmaceuticals Inc. Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes
WO2011161161A1 (en) * 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. A. TAHRANI ET AL, INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, (20070201), vol. 61, no. 2, doi:10.1111/j.1742-1241.2006.01190.x, ISSN 1368-5031, pages 329 - 335. *
D. J. COX ET AL, "Effects of Blood Glucose Rate of Changes on Perceived Mood and Cognitive Symptoms in Insulin-Treated Type 2 Diabetes", DIABETES CARE, (20070801), vol. 30, no. 8, doi:10.2337/dc06-2480, ISSN 0149-5992, pages 2001 - 2002. *
ROSENSTOCK J ET AL, "Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin", MEDLINE, (200104), * abstract * *
WIESLI P ET AL, DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, (20090630), vol. 52, no. 9, doi:10.1007/S00125-009-1439-Z, ISSN 1432-0428, pages 1816 - 1819. *

Also Published As

Publication number Publication date
KR20150001757A (ko) 2015-01-06
RU2014143271A (ru) 2016-05-20
SG11201405433XA (en) 2014-10-30
WO2013144273A1 (en) 2013-10-03
AU2013241776A1 (en) 2014-10-16
CN104334183A (zh) 2015-02-04
IN2014KN02335A (enExample) 2015-05-01
EP2830650A1 (en) 2015-02-04
HK1201155A1 (en) 2015-08-28
US20150065421A1 (en) 2015-03-05
JP2015512908A (ja) 2015-04-30
MX2014011687A (es) 2015-05-11
CA2865823A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
Janez et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
Philis-Tsimikas Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control
US20150065421A1 (en) Basal insulin therapy
Landgraf et al. Therapy of type 2 diabetes
Shrestha et al. National consensus statement on the management of type 2 diabetes mellitus in Nepal
Golden et al. Management of diabetes during acute stroke and inpatient stroke rehabilitation
Mulla et al. Prediabetes: a benign intermediate stage or a risk factor in itself?
Frampton et al. Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
JP2019535791A (ja) 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
Ead Glycemic control and surgery—optimizing outcomes for the patient with diabetes
Class et al. Patent application title: BASAL INSULIN THERAPY Inventors: Peter Johnston (Bridgewater, NJ, US) Hertzel Gerstein (Hamilton, CA) Hertzel Gerstein (Hamilton, CA)
Azeez Present State and Perspectives of Type 2 Diabetes Management
Stefanova et al. Hypoglycaemia: causes, risk factors and pathophysiology
Nazarko Type 2 diabetes: how to manage and treat the condition well
Kanamori et al. Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes
Hudson et al. Diabetes in older adults
P. Toth Effective management of the type 2 diabetes patient with cardiovascular and renal disease: secondary prevention strategies after a myocardial infarction
Cherian et al. Therapeutic implications of diabetes in cardiovascular disease
Wilson Person-centered medication therapy for diabetes in older adults: A practical review
Das et al. Pathophysiology and Clinical Therapeutic Aspects of Diabetes
Valdez et al. Long term evaluation of intensive insulin therapy in patients with type 2 diabetes mellitus
Hiremath Handbook Of Perioperative Care Of Adult Diabetes Patients: Diabetes Care–Before, During And After Surgery
Jang et al. The Early Detection and Managements of Euglycemic Diabetic Ketoacidosis Based on a Rapid Response System: Two Case Reports
Zhen et al. Diabetic Emergencies

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

Free format text: FORMER APPLICANT(S): SANOFI

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee